USA flag logo/image

An Official Website of the United States Government

A novel targeted therapy

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
95866
Program Year/Program:
2010 / SBIR
Agency Tracking Number:
CA141728
Solicitation Year:
N/A
Solicitation Topic Code:
NCI
Solicitation Number:
N/A
Small Business Information
BCN BIOSCIENCES, LLC
BCN BIOSCIENCES, LLC 2275 E FOOTHILL BLVD PASADENA, CA 91107 3658
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2010
Title: A novel targeted therapy
Agency: HHS
Contract: 1R43CA141728-01A2
Award Amount: $160,735.00
 

Abstract:

DESCRIPTION (provided by applicant): Cancer is the leading cause of mortality in the United States, despite many advances in the current therapies including surgery, radiation and chemotherapy. Therefore, it is imperative that novel targets for cancer ther apeutic development are identified and explored in order to improve the outcome of this lethal disease. We recently exclusively licensed a novel gene named EG-1 (endothelial derived gene-1). EG-1 expression is elevated in several cancer epithelial cell typ es, including human breast, colorectal and prostate cancer. Transfection studies showed that over- expression of EG-1 increases cellular proliferation in vitro and xenograft tumor growth in vivo. EG-1 inhibition, whether delivered via siRNA lentivirus or p olyclonal antibody, results in decreased breast cancer cellular proliferation in culture and smaller xenografts in mice. In a series of invasive breast cancer, EG-1 is an independent and significant predictor for survival. Based on this preliminary data, w e hypothesize that EG-1 plays a crucial role in stimulating malignant epithelial cell proliferation. In this research proposal, we will validate the functional significance of EG-1 in breast cancer growth. The specific aim is to suppress breast tumor growt h with EG-1 targeted strategies. We will produce and assess the impact of anti-EG-1 antibodies for their ability to suppress breast cancer growth. The data obtained from this grant proposal will form the basis for the successful translation of the discover y of this molecule into possible human use. PUBLIC HEALTH RELEVANCE: Cancer is the most deadly disease in the United States, and there is an urgent need of new and effective treatments for this lethal condition. This project is highly innovative bec ause: 1) EG-1 is a completely novel gene licensed by our company. It has no significant homology to any known or established gene families. 2) If successful, this research can result in a brand new treatment for epithelial-derived cancer, which is the most common type of malignancy. 3) Because EG-1 is unique, its use as a therapeutic target would not be redundant to other gene products/potential targets involved in other molecular pathways.

Principal Investigator:

Brian Varnum

Business Contact:

Sudip Chakrabortty
andrew@bcnbio.com
Small Business Information at Submission:

BCN BIOSCIENCES, LLC
BCN BIOSCIENCES, LLC 2275 E FOOTHILL BLVD PASADENA, CA 91107

EIN/Tax ID: 133114620
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No